Table 1.
Characteristics of the study cohort
| Total | Pre-vaccine | Post-vaccine dose 1 | Post-vaccine dose 2 | |
|---|---|---|---|---|
| n | 1,090 | 981 | 525 | 239 |
| Age in years, mean (s.d.) | 41.89 (12.18) | 41.60 (12.05) | 43.66 (12.79) | 44.12 (12.65) |
| Race, n (%) | ||||
| White | 509 (46.7) | 453 (46.2) | 263 (50.1) | 130 (54.4) |
| Black or African American | 36 (3.3) | 33 (3.4) | 22 (4.2) | 9 (3.8) |
| Asian | 300 (27.5) | 265 (27.0) | 154 (29.3) | 67 (28.0) |
| Native Hawaiian/Pacific Islander | 29 (2.7) | 27 (2.8) | 14 (2.7) | 3 (1.3) |
| American Indian/Alaska Native | 2 (0.2) | 2 (0.2) | 0 (0.0) | 0 (0.0) |
| Multiple/other | 139 (12.8) | 130 (13.2) | 58 (11.1) | 27 (11.4) |
| Prefer not to answer | 75 (6.9) | 71 (7.2) | 14 (2.6) | 3 (1.3) |
| Ethnicity, n (%) | ||||
| Hispanic/Latinx | 139 (12.8) | 126 (12.8) | 55 (10.5) | 20 (8.4) |
| Non-Hispanic/Latinx | 881 (80.8) | 788 (80.3) | 460 (87.6) | 216 (90.4) |
| Prefer not to answer | 70 (6.4) | 67 (6.8) | 10 (1.9) | 3 (1.3) |
| Sex, n (%) | ||||
| Male | 362 (33.2) | 331 (33.7) | 159 (30.3) | 65 (27.2) |
| Female | 662 (60.7) | 587 (59.8) | 353 (67.2) | 168 (70.3) |
| Other | 1 (0.1) | 1 (0.1) | 1 (0.2) | 1 (0.4) |
| Prefer not to answer | 65 (6.0) | 62 (6.3) | 12 (2.3) | 5 (2.1) |
| Prior SARS-CoV-2 infection, n (%) | 86 (7.9) | 78 (8.0) | 35 (6.7) | 11 (4.6) |
| Antibody levels, mean (%) | ||||
| Architect IgG index (S/C) (IgG(N)) | 0.30 (0.86) | 0.25 (0.84) | 0.36 (0.90) | 0.34 (0.82) |
| Architect IgM index (S/C) | 0.99 (2.41) | 0.26 (1.24) | 2.11 (4.11) | 3.38 (5.96) |
| Architect Quant IgG II (AU ml−1) (IgG(S-RBD)) | 2,801.04 (6,159.27) | 103.90 (693.89) | 3,183.38 (7,299.73) | 24,084.06 (16,367.63) |